Background {#Sec1}
==========

Rectus sheath block (RSB) was introduced into clinical practice in 1899 by Schleich, and it involves blocking the ventral rami of the 7th to 12th intercostal nerves by the injection of a local anesthetic into the space between the rectus muscle and posterior rectus sheath to achieve analgesic effects \[[@CR1], [@CR2]\]. With the development of long-acting local anesthetic agents, such as ropivacaine, and ultrasonic technology, RSB has become safer and more effective \[[@CR3], [@CR4]\].

RSB is usually performed before surgery for patients with general anesthesia because it inhibits reflection of the skin incision and reduces the amount of intraoperative anesthetic used \[[@CR5]--[@CR8]\]. Postoperative surgical RSB appears to provide effective postoperative analgesia for patients undergoing major gynecological surgery \[[@CR9]\], and the postoperative placement of RSB analgesia does not significantly alter the oxidative stress marker concentrations in patients with benign disease or cancer \[[@CR10]\].

The peripheral inflammatory response to surgery may influence patient outcomes, such as postoperative sleep, and we have published two clinical trials on this topic using the bispectral index (BIS) to monitor sleep \[[@CR11], [@CR12]\]. Postoperative sleep disturbances after surgery can be caused by factors such as the anesthesia used, pain and sympathetic activation and psychological responses \[[@CR13]\]. However, little information is available about the effect of RSB on sleep quality and the inflammatory response during the immediate postoperative period. In particular, there is no information about whether preoperative block or postoperative block will benefit patients.

The primary hypothesis is that performing RSB after surgery would result in a longer duration of analgesic effects. The secondary hypothesis is that performing RSB after surgery have a longer duration of sleep after surgery but that it would not decrease the perioperative cytokine levels of patients undergoing gynecological surgery. The null hypothesis is there is no difference between performing RSB before surgery and after surgery.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This study is a prospective, randomized, controlled, and double-blinded trial. Major assessments were made during the operation and 48 h postoperatively. We followed the Consolidated Standards of Reporting Trials (CONSORT) recommendations in designing and reporting the findings of our study. The trial was approved by the Ethics Committee of the First Hospital of China Medical University (protocol number 2015110901, Chairman Prof. Xing-hua Gao, January 14, 2015, Trial registration: NCT02477098, Principal investigator's name: Wen-fei Tan, Date of registration: 2015--06-15 <https://clinicaltrials.gov/ct2/show/NCT02477098?term=NCT02477098&rank=1>). We changed our published protocol \[[@CR14]\] (protocol number 2014071701) from a single-blind to a new double-blind trial with approval from the Ethics Committee. All participants provided written informed consent in accordance with the Declaration of Helsinki.

Patients {#Sec4}
--------

Seventy-seven patients undergoing elective transabdominal gynecological surgery were enrolled in this study from October 2015 to June 2016 at the First Hospital of China Medical University. The patients in this trial were visited 24 h and 48 h postoperatively by one of the research personnel. Sleep quality during the first postoperative night was assessed using the BIS data, and venous blood was collected.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

The inclusion criteria were as follows: (1) age 18 to 65 years; (2) scheduled to undergo elective midline incision (8--10 cm) transabdominal gynecological surgery for a benign mass (ovarian or uterine); and (3) American Society of Anesthesiologists (ASA) risk classification I-II.

The exclusion criteria were as follows: (1) patient refusal; (2) known hypersensitivity to the study medication (ropivacaine); (3) long-term use of opioids; (4) liver or renal insufficiency; (5) a history of psychiatric or neurological disease; (6) deafness; (7) previous open surgery; (8) regular use of acetaminophen, nonsteroidal anti-inflammatory drugs, corticosteroids, or antiemetics; and (9) a preoperative Pittsburgh Sleep Quality Index (PSQI) global score higher than 6.

Randomization and masking {#Sec6}
-------------------------

All patients requiring transabdominal gynecological surgery were randomly assigned via computer-generated sequences placed into sealed envelopes to the following two groups: a general anesthesia group receiving 0.5% ropivacaine hydrochloride RSB (Group PRE) preoperatively and saline RSB postoperatively; and a general anesthesia group receiving preoperative saline RSB and 0.5% ropivacaine hydrochloride RSB postoperatively (group POST). Treatment allocation was revealed by opening the envelope on the morning of surgery. All of the patients, the anesthesiologist performing the block, and the staff involved in postoperative data collection and analyses were blinded to the group allocations. The trial was monitored by an independent data and safety monitoring organization. The group allocations were not revealed until the final statistical analysis was completed.

Interventions {#Sec7}
-------------

### Before anesthesia {#Sec8}

All patients were assessed with the PSQI one day before the operation \[[@CR15]\]. The PSQI differentiates between good sleepers (PSQI global score \< 6) and poor sleepers (PSQI global score ≥ 6) with high sensitivity and specificity. The patients in this study received routine general anesthesia and surgery. No additional requirements or preoperative oral analgesics were permitted. While the patients were in the operating room, standard monitoring was performed, including evaluations of systolic blood pressure, diastolic blood pressure, heart rate, electrocardiography, blood oxygen saturation and the BIS. After venipuncture, 3 ml of venous blood was collected for plasma inflammatory cytokine measurements prior to induction. Plasma samples were used to measure the cytokine concentrations (interleukin-6 \[IL-6\], tumor necrosis factor-α \[TNF-α\], IL-1β and interferon-gamma \[IFN-γ\]) in all patients. Commercially available radioimmunoassay kits were used to measure the plasma concentrations of IFN-γ, IL-1β, IL-6, and TNF-α (eBioscience, Bender MedSystems GmbH, Vienna, Austria).

### General anesthesia {#Sec9}

All operations performed in the study were completed between 08:00 am and 12:00 noon by the same group of surgeons. General anesthesia was induced with 2 mg/kg intravenous (IV) propofol, 2 mg of IV midazolam, 0.4 μg/kg IV sufentanil, and 0.2 mg/kg IV cisatracurium. The tidal volume was adjusted to 6--8 ml/kg, and the ventilator rate was adjusted to maintain end-tidal CO~2~ at 35--45 mmHg. For the maintenance of anesthesia, sevoflurane (Baxter Healthcare of Puerto Rico, Guayama, Puerto Rico) was used at an end-tidal concentration of 2--2.5%, and an air-oxygen (FiO~2~: 50%) mixture was adjusted for the maintenance of anesthesia with the intraoperative titration of IV sufentanil after intubation in both groups. An additional cisatracurium dose (0.05 mg/kg) was applied if needed. At the end of surgery, the trachea was extubated after the return of spontaneous respiration and neuromuscular function, and the patient was then transferred to the post-anesthesia care unit (PACU). The patients received pain relief (visual analogue scale (VAS) score of less than 3) using 5--10 μg of titrated sufentanil. Three milliliters of venous blood was collected for plasma inflammatory cytokine measurements at the PACU.

### RSB technique {#Sec10}

Before and at the end of surgery, a bilateral single-shot RSB of 15 ml of solution was performed under ultrasound guidance by the same anesthesiologist. The rectus muscle was imaged with an ultrasound probe in the transverse orientation at the level of the umbilicus. A broadband (5--12 MHz) linear array ultrasound probe (S-Nerve Ultrasound System, SonoSite, Bothell, Washington, USA) was used with an imaging depth of 4--6 cm. A PAJUNK (PAJUNK, GmbH, Medizintechnologie, Geisingen, Germany) insulated needle (50 mm, 21 gauge) was introduced a few millimeters from the probe using an in-plane technique at an angle of approximately 45 degrees to the skin 1 cm to the side and down from the navel. The ultrasound imaging allowed for the identification of the rectus muscle and two hyperechoic railway-like lines deep in this muscle (the posterior rectus sheath and the peritoneum). Under direct vision, the needle tip was advanced to the desired position, where 15 ml of solution was injected, causing hydrodissection of the rectus muscle away from the posterior rectus sheath on each side. The technique was repeated on the opposite side. The procedure was performed by one investigator using a completely aseptic technique. In group PRE, 15 ml of 0.5% ropivacaine hydrochloride RSB before surgery and 15 ml of saline RSB at the end of surgery was administered on each side. An opposite block sequence was performed in group POST.

### Postoperative analgesia: Patient-controlled intravenous analgesia (PCIA) {#Sec11}

All of the patients, irrespective of the group allocation, received PCIA with oxycodone. A PCIA pump (AponZZB-I50, Nantong, China) was set up with a bolus injection of 2 mg every 5 min for a maximum of 10 mg every 4 h without basal infusion. The PCIA pump was stopped 48 h postoperatively, and postoperative nausea and vomiting were treated with 5 mg IV tropisetron (in the ward).

### Postoperative nocturnal sleep: The BIS-vista monitor {#Sec12}

Postoperative nocturnal sleep was evaluated with the BIS-Vista monitor (Aspect Medical Systems, Norwood, MA, USA), and three outcome measures were used in this study: the area under the curve (AUC) and sleep stages N2 and N3 \[[@CR16]\]. A cutoff of BIS \< 55, with a sensitivity of 87% and specificity of 93%, was identified as stage N3 in this trial. The BIS threshold that identified stage N2 was \< 73 \[[@CR17]\]. The observation period included 11 h of monitoring (from 19:00 pm to 06:00 am). The BIS-AUC was calculated using the trapezoidal rule, which uses trapeziums to approximate the region under a curve and to calculate its area (GraphPad Prism version 5.01). Each night, the AUC values were set to missing if the recordings were less than 11 h in duration.

Study outcomes {#Sec13}
--------------

The primary objective was to compare the interval between leaving the PACU and receiving the first PCIA bolus injection on the first postoperative night between patients who received preoperative RSB and those who received postoperative RSB. The secondary objectives were to compare the following: (1) cumulative oxycodone consumption at 48 h after surgery between patients who received preoperative versus postoperative RSB; (2) postoperative sleep status, which was measured using a BIS-Vista monitor during the first night after surgery; and (3) cytokine levels (IFN-γ, IL-1β, IL-6, and TNF-α), which were compared during the operation and at 24 and 48 h postoperatively.

Criteria for removal from the study {#Sec14}
-----------------------------------

During the study, patients found to have the following were removed from the study: (1) a loss of over 500 ml of blood during surgery; (2) an operation time of longer than 3 h; (3) a violation of the trial protocol; or (4) a desire to withdraw from the study.

Sample size {#Sec15}
-----------

Sample size was calculated on the basis of the average (mean ± standard deviation \[SD\]) interval between leaving the PACU and the receipt of the first PCIA bolus injection on the first postoperative night calculated, which was calculated in the pilot study (group PRE: 203.2 ± 21.5 min; and group POST: 258.2 ± 98.7 min). The formula for determining sample size \[[@CR18]\] was *n* = 15.7/ES^2^ + 1, where ES is the effect size, defined as the difference between the groups divided by the mean of the SD between the groups, with α = 0.05 and power = 0.8. The study was adequately powered, with *n* = 32 in each group.

Statistical analysis {#Sec16}
--------------------

Statistical analysis was performed using SPSS software, version 22 for Windows (IBM, Armonk, NY, USA). A fully specified statistical analysis protocol was written in an independent manner. Before statistical testing, each continuous variable was analyzed to determine whether it had a normal distribution using the Kolmogorov-Smirnov test. Continuous data are described as the mean (SD) or median (25% and 75% percentiles) and were analyzed with the independent t-test or the Mann-Whitney U test, respectively. Categorical data are described as a frequency or percentage and were analyzed by the chi-square test. Repeated-measures ANOVA was used to determine differences in the cytokine levels within and between the groups. For intervals between leaving PACU and the first PCIA trigger, we analyzed data using the Kaplan-Meier survival method and compared groups using the log-rank test. A *P* value \< 0.05 was considered statistically significant.

Results {#Sec17}
=======

Patient characteristics {#Sec18}
-----------------------

Of the 77 potential patients assessed for eligibility, 13 patients were excluded; thus, 64 patients were randomly assigned to two groups. One patient was lost to follow-up because of a BIS equipment error, and one patient in group PRE was excluded from the analysis because of missing BIS data. One patient in group POST was excluded from the analysis because of failure to use PCIA. A total of 61 female patients (mean age: 50 years; range: 24--65 years) were included in the final study sample (Fig. [1](#Fig1){ref-type="fig"}). Group sample sizes of 30 and 31 achieve 85% power with a significance level (alpha) of 0.05 using a one-sided two-sample t-test with PASS11 software (NCSS LLC, Utah, USA). Table [1](#Tab1){ref-type="table"} presents the results of the demographic and preoperative characteristics of the two groups. There was no significant difference in these characteristics between the two groups.Fig. 1Patient flowchart showing the patients included in enrollment, group allocation, follow-up, and analysis phases of the studyTable 1Patient demographic data and characteristicsVariableGroup PREGroup POST95% Confidence interval*P*(*n* = 30)(*n* = 31)Age (years)47.1 ± 13.845.5 ± 10.60.625^b^Body mass index (kg/m^2^)24.8 ± 2.922.9 ± 2.60.625^b^ASA (I/II)19/1118/130.674^c^Pittsburgh Sleep Quality Indexglobal score3.0\[2.0,3.5\]3.0\[2.0,4\]0.518^a^*Intraoperation* Duration of anesthesia (min)131.1 ± 20.4133.9 ± 28.8(− 15.6,10.0)0.663^b^ Duration of surgery (min)79.7 ± 17.176.8 ± 21.7(− 7.1,12.9)0.570^b^ Volume loading (ml)1413.3 ± 351.11441.9 ± 354.8(− 9.5,352.3)0.763^b^ Bleed amount (ml)150\[120,205\]150\[130,230\]0.930^a^ Length of skin incision (cm)9.0\[8.0,9.5\]9.0\[8.0,10.0\]0.951^a^ Sufentanil (μg)47.3 ± 4.147.1 ± 4.8(−2.1,2.5)0.837^b^Values represent the mean ± SD, the number of patients, or the median \[25th percentile, 75th percentile\]^a^Mann--Whitney U test^b^Student's *t* test^c^chi-square test

VAS and PCIA data {#Sec19}
-----------------

The interval between leaving the PACU and receiving the first PCIA bolus injection on the first postoperative night was 211.5 min and 229.1 min in groups PRE and POST respectively (Table [2](#Tab2){ref-type="table"}). The Kaplan-Meier survival analysis of the interval between leaving the PACU and receiving the first PCIA bolus injection for the two groups is shown in Fig. [2a](#Fig2){ref-type="fig"}. The log-rank test also suggested no detectable difference between the two groups (*P* = 0.736). There was no significant difference in the VAS, consumption of oxycodone, or time to first PCIA trigger between the two groups.Table 2Visual analogue scale and patients control intravenous analgesia dataVariableGroup PREGroup POST95% Confidence interval*P*(*n* = 30)(*n* = 31)Visual analogue scale (24 h)2.0 \[0.5,3.0\]2.0 \[1.0,3.0\]0.534^a^Visual analogue scale (48 h)1.0 \[1.0,2.0\]1.0 \[0,2.0\]0.685^a^Time to first PCIA trigger (min)211.5 ± 35.3229.1 ± 42.1(− 126.3,91.3)0.523^b^Consumption of oxycodone during 24 h (mg)32 \[24,52\]32 \[16,56\]0.749^a^Consumption of oxycodone from 24 h to 48 h (mg)4 \[0,4\]4 \[0,20\]0.443^a^Values represent the mean ± SD, or the median \[25th percentile, 75th percentile\]^a^Mann--Whitney U test^b^Student's t testFig. 2Kaplan-Meier survival plot representing time to first PCIA trigger (**a**), examples of BIS data on the first postoperative night in the two groups (**b**), and a picture of one incision (**c**). **a** The log-rank test suggested no detectable difference between the two groups (*P* = 0.736). **c** The white arrow shows fluid in the rectus sheath

BIS-AUC and sleep stages N2 and N3 during the entire nocturnal sleep period {#Sec20}
---------------------------------------------------------------------------

The BIS-AUC in group PRE was lower than that in group POST, indicating "better" sleep in the PRE group \[[@CR16]\] (Table [3](#Tab3){ref-type="table"}). Furthermore, the time spent in sleep stages N2 and N3 was significantly increased by 52.9 min and 29.1 min, respectively, in group PRE compared to group POST. One example of the first postoperative night BIS data of the two groups is shown in Fig. [2b](#Fig2){ref-type="fig"}.Table 3BIS data of patients in the two groups on the first postoperative nightBIS dataGroup PREGroup POST95% Confidence interval*P*(*n* = 30)(*n* = 31)BIS-AUC (%)82.5 \[81.8, 84.7\]86.5 \[86.4.7, 86.9\] ^a^\<  0.001Stage N2 sleep (min)134.0 ± 10.781.1 ± 10.6^b^(42.9,62.9)\< 0.001Stage N3 sleep (min)54.5 ± 12.425.4 ± 7.9^b^(19.2,39.2)\< 0.001Values represent the median \[25th percentile, 75th percentile\] and the mean ± SD*BIS* bispectral index, *SEI* sleep efficiency index, *AUC*, area under the curve^a^Mann--Whitney U test^b^Student's t test

Cytokine levels and their correlation with the BIS data {#Sec21}
-------------------------------------------------------

There was a significant difference in the all cytokine levels between the two groups (Fig. [3](#Fig3){ref-type="fig"}). In group POST, the concentrations of four cytokines were higher compared to those in group PRE (*P* \<  0.05; Fig. [3a-d](#Fig3){ref-type="fig"}). IL-6 concentration increased during the postoperative 48 h compared to baseline in both groups, but the IL-6 concentration in group PRE was lower than that in group POST at the end of surgery and 24 h postoperatively (*P* \<  0.001; Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3Comparison of the plasma concentrations of IL-1β (**a**), IL-6 (**b**), IFN-γ(**c**), and TNF-α (**d**) between the two groups. **a** *P*~group~ = 0.048, *P*~time~ = 0.285, and *P*~group-time\ interaction~ = 0.865. **b** *P*~group~, *P*~time~, and *P*~group-time\ interaction~ \<  0.001. ^\#^*P* \<  0.001 vs. baseline. **c** *P*~group~ \<  0.001, *P*~time~ = 0.949, and *P*~group-time\ interaction~ = 0.120. **d** *P*~group~ = 0.003, *P*~time~ = 0.325, and *P*~group-time\ interaction~ = 0.298

Discussion {#Sec22}
==========

The results of this study suggest that there is no difference in the first PCIA remedy trigger between patients who undergo elective transabdominal gynecological surgery with preoperative RSB or postoperative RSB. Patients with preoperative RSB may have better sleep preservation than patients treated with postoperative RSB. Compared to the postoperative RSB group, the concentrations of all cytokines tested were lower in the preoperative RSB group. IL-6 in the postoperative RSB group increased compared to the preoperative group at the end of surgery and 24 h postoperatively.

Two questions that motivated this clinical trial can be answered. First, surgeons always found "water" in their incision when the RSB was performed preoperatively (white arrow, Fig. [2c](#Fig2){ref-type="fig"}). They suggested performing RSB postoperatively because the leakage of drugs would attenuate the effect. However, the stability of preoperative RSB hemodynamics (data not shown) encouraged the anesthesiologists to finish the block as early as possible. In the postoperative period the anesthesiologists were concerned about the changes in the local anatomy and distortion of nerve elements. However, a block after surgery will theoretically prolong the effective time of the local anesthetic. For elective transabdominal gynecological surgery lasting no more than 3 h, there is no difference in the opioid consumption and the first remedy trigger time between preoperative and postoperative RSB. In one study, Wulf et al. \[[@CR19]\] reported that the arterial ropivacaine level after the block (ilioinguinal iliohypogastric block, 20 ml of 0.5% ropivacaine) peaked at 30 min. The onset time of the local anesthetic in the nerve terminal may be less than the peak concentration time \[[@CR20]\]. The interval between a completed RSB procedure and the incision is nearly 30 min in our center, which is usually enough time for 0.5% ropivacaine to work on the nerve terminal. Although the surgeons will find "water" in the incision, the nerve block will be complete. The change in the local anatomy and the apocoptic nerve terminal will not prolong the effect of the local anesthetic as expected.

Second, the surgery-related postoperative release of the proinflammatory IL-6 cytokine is increased in patients after spinal and general anesthesia \[[@CR21]\]. Increased IL-6 levels may be associated with alterations in sleep in the context of pathological or other conditions \[[@CR22]\]. In our previous study, we found that patients receiving epidural analgesia may have preserved sleep quality on the first night after surgery due to better pain management and inhibition of increasing IL-6 levels \[[@CR11]\]. The upregulation of IL-6 at central sites is an important component of the surgery-induced inflammatory response in patients and may influence postoperative sleep \[[@CR23]\]. Plasma IL-6 levels are correlated with non-rapid eye movement sleep, rapid eye movement sleep and fatigue \[[@CR24]\]. In this trial, the preoperative RSB not only exhibited stable hemodynamics, as shown by the monitoring data, but also inhibited the upregulation of all cytokines tested, specifically IL-6. Inhibition of the upregulation of cytokines may thus influence postoperative sleep as recorded by a BIS monitor.

This trial produced an interesting result. No complaints were reported regarding the presence of the urethral catheter in our female patients undergoing a transabdominal gynecological operation before the use of RSB. However, in the pilot study of this trial, more patients complained about the presence of the urethral catheter and preferred the pain of an incision. This phenomenon suggested that the somatic pain of the incision masked the visceral pain of the urethral catheter in our previous technique. Covering the urethral catheter in local anesthetic cream, RSB and PCIA with oxycodone is a potentially better multimodal analgesic technique for patients undergoing transabdominal gynecological surgery with an open midline incision.

This study has several limitations. The main deficiency was the lack of validation of a full polysomnogram. We also need to observe the postoperative sleep disturbance for more days after the operation. Finally, our study included only female patients and thus does not avoid gender bias.

Conclusions {#Sec23}
===========

There is no difference in the first PCIA remedy trigger or opioid consumption between the two groups. Patients with preoperative RSB may have better sleep preservation than patients treated with postoperative RSB. Compared to the postoperative RSB group, the concentrations of all cytokines tested were lower in the preoperative RSB group. We conclude that preoperative RSB might preserve the first postoperative sleep by inhibiting the increase in IL-6 without shortening of analgesic time compared with postoperative RSB in female patients undergoing elective midline incision transabdominal gynecological surgery.

PACU

:   Postanesthesia care unit

PCIA

:   Patient-controlled intravenous analgesia

PSQI

:   Pittsburgh Sleep Quality Index

RSB

:   Rectus sheath block

VAS

:   Visual analogue scales
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